This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $271.73 in the latest trading session, marking a +0.3% move from the prior day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $270.12, moving -1.85% from the previous trading session.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $264.39 in the latest trading session, marking a +1.05% move from the prior day.
Dow Jones Beats S&P 500 in 2022: 5 Hot Stocks
by Sweta Killa
The Dow Jones fared as the best of the indexes and five stocks -- Chevron (CVX), Merck (MRK), Travelers (TRV), Amgen (AMGN), and Caterpillar (CAT) -- gained in double-digits in 2022.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $263.16 in the latest trading session, marking a +0.67% move from the prior day.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Ideas feature highlights: Caterpillar, Chevron and Amgen
by Zacks Equity Research
Caterpillar, Chevron and Amgen have been highlighted in this Investment Ideas article.
3 Top Performing Blue-Chips of 2022
by Derek Lewis
Many investors have flocked to blue-chip stocks in 2022 to shield themselves from volatility. Can the strength of these three stocks spill into 2023?
Amgen (AMGN) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $263.39, moving -0.2% from the previous trading session.
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.
The Zacks Analyst Blog Highlights Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial
by Zacks Equity Research
Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial are part of the Zacks top Analyst Blog.
Q4 Earnings Season Update and Analyst Reports for Broadcom, UPS & Amgen
by Sheraz Mian
Today's Research Daily features update on the Q4 earnings season and new research reports on Broadcom (AVGO), UPS (UPS), Amgen (AMGN) and 16 other stocks.
Amgen (AMGN) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $265.70, marking a -0.64% move from the previous day.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
5 Stocks to Watch on Dividend Hikes Before 2022 Wraps Up
by Zacks Equity Research
Investors may keep a tab on LW, NUE, PWRr, TTC, and AMGN which have lately hiked their dividend payments to reward investors.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $272.26, marking a -1.63% move from the previous day.
Trending Today: 5 Stocks in the News
by Andrew Rocco
So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
by Sweta Killa
Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
5 Dow Stocks That Helped the Index Minimize Loss in 2022
by Vaishali Doshi
Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.